Table 1.
Demographic And Baseline Data Of Patients In The Treated Set (N=7443)
| Variable | |
|---|---|
| Age at registration | |
| Mean, years (SD) | 65.1 (9.3) |
| ≤65 years, n (%) | 3783 (50.8) |
| >65–<75 years, n (%) | 2438 (32.8) |
| ≥75 years, n (%) | 1222 (16.4) |
| Sex | |
| Male, n (%) | 5094 (68.4) |
| Patients with concomitant diseases | |
| n (%) | 5366 (72.1) |
| Patients taking concomitant medication (except respiratory therapeutics) | |
| n (%) | 4482 (60.2) |
| Smoking status | |
| Smoker, n (%) | 3080 (41.4) |
| Ex-smoker, n (%) | 3325 (44.7) |
| Never smoked, n (%) | 1038 (14.0) |
| Pack-years | |
| Mean (SD) | 35.1 (19.8) |
| Duration between initial diagnosis and baseline visit | |
| Years, mean (SD) | 4.8 (5.86) |
| COPD degree of severity, spirometric | |
| Patients in stage GOLD 1, n (%) | 119 (1.60) |
| Patients in stage GOLD 2, n (%) | 3379 (45.40) |
| Patients in stage GOLD 3, n (%) | 3111 (41.80) |
| Patients in stage GOLD 4, n (%) | 744 (10.00) |
| mMRC Questionnaire | |
| Patients with grade 0, n (%) | 238 (3.2) |
| Patients with grade 1, n (%) | 1763 (23.7) |
| Patients with grade 2, n (%) | 3157 (42.4) |
| Patients with grade 3, n (%) | 1874 (25.2) |
| Patients with grade 4, n (%) | 411 (5.5) |
| GOLD group, based on symptoms and exacerbations only (version 2017) | |
| Patients in group A, n (%) | 1625 (21.8) |
| Patients in group B, n (%) | 3639 (48.9) |
| Patients in group C, n (%) | 376 (5.1) |
| Patients in group D, n (%) | 1803 (24.2) |
| Exacerbations in the 12 months prior to the study | |
| Number of exacerbations | 8014 |
| Patients with at least one event, n (%) | 4831 (64.9) |
| Mean (SD) | 1.1 (1.1) |